Searched for: in-biosketch:yes
person:freids01
An international comparative study of HIV prevalence and risk behaviour among drug injectors in 13 cities. WHO Collaborative Study Group
[WHO Collaborative Study Group; Friedman, Samuel R; et al]
Although reported rates of human immunodeficiency virus (HIV) infection and related risk behaviours among drug injectors vary considerably throughout the world, and comparison of findings is often hampered by methodological variability among centres. In 1989 the World Health Organization initiated a comparative study of current drug-injecting behaviour and HIV infection using a standardized methodology. Centres were asked to recruit at least half of their samples outside drug treatment settings in order to achieve as representative a group of injectors as possible. Respondents were interviewed using a questionnaire designed by an international working group, and they were asked to provide blood and/or saliva specimens for voluntary testing. Data from 13 centres (Athens, Bangkok, Berlin, Glasgow, London, Madrid, Naples, New York, Rome, Rio de Janeiro, Santos, Sydney and Toronto) are reported here. A total of 6,390 injectors were recruited to the study from October 1989 to March 1992, with sample sizes ranging from 85 at Santos (Brazil) to 1,300 in New York. Weekly or daily sharing of injecting equipment was reported by less than a quarter of injectors in all centres. A high proportion of those sharing made some effort to clean equipment before use, although not always by efficient methods. In all centres, the majority of respondents were sexually active; however, rates of unprotected sexual intercourse were high, particularly between regular sexual partners. The overall HIV prevalence rate was 22 per cent, ranging from 0 per cent in Athens to 60 per cent in Santos. Caution should be exercised in postulating a link between HIV prevalence and current risk behaviour, particularly since injectors appear to behave in similar ways across a diverse range of study locations. This is the first report on an international collaborative study for which a large number of injectors were successfully recruited from a variety of settings. The wealth of data now available provides a greater understanding of the social epidemiology of drug injecting, which is essential for the implementation and evaluation of campaigns and interventions designed to limit the spread of HIV infection.
PMID: 8305904
ISSN: 0007-523x
CID: 4844702
Changing the culture of risk
Chapter by: Friedman, Samuel R; Wiebel, W; Jose, B; Levin, L
in: Handbook on risk of AIDS : injection drug users and sexual partners by Brown, Barry S; Beschner, George M (Eds)
Westport, Conn. : Greenwood Press, 1993
pp. 499-516
ISBN: 9780313283741
CID: 4848862
Drug policy and AIDS among drug injectors
Friedman, Samuel R; Ward, TP
ORIGINAL:0015029
ISSN: 0955-3959
CID: 4848852
Prospects for HIV infection and AIDS among drug injectors in Rio de Janeiro : perspectives and unanswered questions
Lima, ES; Bastos, FI; Friedman, Samuel R
ORIGINAL:0015028
ISSN: 0007-523x
CID: 4848842
Going beyond education to mobilizing subcultural changes
Friedman, Samuel R; Des Jarlais, DC
ORIGINAL:0015019
ISSN: 0955-3959
CID: 4848132
HIV seroconversion among street-recruited drug injectors
Friedman, Samuel R; Des Jarlais, Don C; Deren, S; Jose, B; Neaigus, A; National AIDS Research Consortium
ORIGINAL:0015048
ISSN: n/a
CID: 4856502
Drug injectors and HIV: New issues arise, yet many old ones remain unresolved
Friedman, S. R.
SCOPUS:0027104259
ISSN: 0887-3852
CID: 4847722
International epidemiology of HIV and AIDS among injecting drug users [Editorial]
Des Jarlais, D C; Friedman, S R; Choopanya, K; Vanichseni, S; Ward, T P
PMID: 1466837
ISSN: 0269-9370
CID: 3603552
AIDS AND LEGAL ACCESS TO STERILE DRUG INJECTION EQUIPMENT
DESJARLAIS, DC; FRIEDMAN, SR
Legal access to sterile injection equipment has been a primary strategy for preventing the acquired immune deficiency syndrome (AIDS) among persons who inject illicit drugs in almost all developed countries. This strategy has remained highly controversial in the United States, with only a small number of localities adopting it. This article reviews different techniques of providing legal access-over-the-counter sales and syringe exchanges-research design issues relevant to evaluating legal-access programs, and the findings from the large number of studies conducted to date. The findings are consistent in showing no increase in illicit drug use related to legal access and decreases in AIDS risk behavior related to legal-access programs. The design of legal-access programs for maximal impact and the ultimate effect of the decreases in AIDS risk behavior on transmission of the human immunodeficiency virus (HIV) remain to be determined. ISI:A1992KR64800004
ISSN: 0002-7162
CID: 3606252
AIDS and the transition to illicit drug injection--results of a randomized trial prevention program
Des Jarlais, D C; Casriel, C; Friedman, S R; Rosenblum, A
Illicit drug injection is a major component of the AIDS epidemic in the United States, Europe and some developing countries. Prevention of illicit drug injection would not only reduce HIV transmission but would also reduce the other health, psychological and social problems associated with illicit drug injection. One hundred and four subjects who were using heroin intranasally ('sniffing') were recruited for a study of the transition to drug injection. Eligibility criteria included sniffing as the most frequent route of administration and no more than 60 injections in the past 2 years. All subjects received thorough basic information about AIDS, including HIV antibody test counseling. Subjects were then randomly assigned to a four-session social learning based AIDS/drug injection prevention program or a control condition. Eighty-three subjects were successfully followed at a mean time of 8.9 months. Twenty (24%) of the followed subjects reported injecting illicit drugs during the follow-up period. Drug injection during follow-up was associated with being in the control group, intensity of non-injected drug use, prior injection, and having close personal relationships with current intravenous (IV) drug users.
PMID: 1559048
ISSN: 0952-0481
CID: 3603612